Cancer Immunotherapy: 2022 Research and a Look Ahead with E. John Wherry, Ph.D.

Renowned cancer immunotherapy expert E. John Wherry, Ph.D., discusses new research and treatments in the year ahead. #Immunotherapy #CRIwebinar https://www.cancerresearch.org/webinars

- Promising new treatment strategies in patient care including combination treatments
- What biomarkers are and how they’re important to formulating a treatment plan
- Latest advances in cellular immunotherapy for solid tumors

E. John Wherry, Ph.D., is the director of the Institute for Immunology, the chair of the Department of Systems Pharmacology and Translational Therapeutics, and the Richard and Barbara Schiffrin President’s Distinguished Professor at the University of Pennsylvania Perelman School of Medicine. He is also an associate director of the Cancer Research Institute Scientific Advisory Council. A leader in understanding T cell biology in the context of chronic infection and cancer, Dr. Wherry has published more than 200 papers and his research has been cited nearly 50,000 times in peer-reviewed publications.

Cancer Immunotherapy and You Webinars™ are produced by the Cancer Research Institute and hosted by CRI Assistant Director of Scientific Content Arthur N. Brodsky, Ph.D. The 2022 series is made possible with generous support from Bristol Myers Squibb and Lilly Oncology.

Browse our Cancer Immunotherapy and You Webinars playlist on YouTube or visit the Webinars page on our website to see other webinars in this series. https://www.cancerresearch.org/webinars

Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org

Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.